Table 2.
Patient | Average number of DC administrated (106) | Average number of CIK administrated (108) | Serum CEA | Toxicity of skin (°) | Non-infective fever (°) |
---|---|---|---|---|---|
1 | 11.5 ± 1.9 | 18.9 ± 2.3 | ↑ | 0 | I |
2 | 6.5 ± 0.98 | 12.5 ± 2.5 | ↓ | I | III |
3 | 7.6 ± 1.7 | 11.3 ± 0.8 | → | II | I |
4 | 12.25 ± 2.8 | 11.2 ± 2.2 | → | 0 | 0 |
5 | 5.4 ± 2.5 | 9.9 ± 0.4 | → | 0 | I |
6 | 6.6 ± 0.85 | 19.4 ± 0.8 | → | II | 0 |
7 | 7.5 ± 3.3 | 10.8 ± 0.9 | → | III | 0 |
8 | 8.2 ± 0.8 | 16.3 ± 2.2 | → | I | I |
9 | 5.5 ± 2.5 | 17.7 ± 0.6 | → | II | 0 |
10 | 10.5 ± 0.7 | 13.8 ± 1.9 | ↓ | III | II |
11 | 8.9 ± 0.7 | 9.7 ± 0.4 | ↑ | 0 | I |
12 | 8.2 ± 1.0 | 10.4 ± 0.9 | ↓ | I | IV |
13 | 6.7 ± 0.9 | 10.9 ± 1.1 | → | 0 | III |
14 | 10.4 ± 2.6 | 11.8 ± 1.2 | → | II | II |
The average number of immune cells and adverse event in each patient of chemoimmunotherapy group were shown. CEA level decreased in 3 patients (21.4%), while it was stable in 9 patients (64.2%)